SCHEMBL1710683

SCHEMBL1710683

CC(C)(C1CCN(Cc2ncc(C(F)(F)F)cc2Cl)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
CYP3A4 P08684 2/20 0.42
CACNA1B Q00975 2/20 0.42
NR1I2 O75469 1/20 0.42
ALDH1A1 P00352 4/20 0.41
LMNA P02545 2/20 0.41
USP2 O75604 2/20 0.41
NPSR1 Q6W5P4 2/20 0.40
HPGD P15428 3/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 2/20 0.38
POLB P06746 1/20 0.38
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GAA P10253 2/20 0.36
HSD11B1 P28845 1/20 0.36
CNR1 P21554 1/20 0.36
RORC P51449 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2189347 0.86 CACNA1B (0.45) CYP3A4CACNA1BNR1I2ALDH1A1LMNA
SCHEMBL2190237 0.84 CYP3A4 (0.45) KMT2ACYP3A4CACNA1BNR1I2ALDH1A1
SCHEMBL2188590 0.84 CYP3A4 (0.45) KMT2ACYP3A4CACNA1BNR1I2ALDH1A1
SCHEMBL2189164 0.84 CYP3A4 (0.46) CYP3A4CACNA1BNR1I2ALDH1A1LMNA
SCHEMBL2187144 0.84 LMNA (0.50) KMT2ACYP3A4CACNA1BNR1I2ALDH1A1
SCHEMBL2187135 0.83 ALDH1A1 (0.47) CYP3A4CACNA1BNR1I2ALDH1A1LMNA
SCHEMBL2190814 0.83 ALDH1A1 (0.47) CYP3A4CACNA1BNR1I2ALDH1A1LMNA
SCHEMBL2190524 0.82 CYP3A4 (0.45) KMT2ACYP3A4CACNA1BNR1I2ALDH1A1
SCHEMBL2188485 0.82 CACNA1B (0.52) CYP3A4CACNA1BNR1I2ALDH1A1LMNA
SCHEMBL2189634 0.81 CACNA1B (0.51) CYP3A4CACNA1BNR1I2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344450-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Merck Sharp & Dohme Corp. (US) 2011-07-20 EP claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
WO-2010036589-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. (US) 2010-04-01 WO claimed
EP-2344450-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Merck Sharp & Dohme Corp. (US) 2011-07-20 EP disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
WO-2010036589-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. (US) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D KMT2A 2427/4885CYP3A4 939/4885CACNA1B 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.